

<ul style="list-style-type: none"> • Øyvinn A. Brøymer, Styreleder (gjenvallgt) • Bettina Banoun (gjenvallgt) • Kari Krogstad (gjenvallgt) • Espen Marcussen (gjenvallgt) <p>Styret består da av følgende aksjonærvallgte og ansatte vallgte medlemmer:</p> <ul style="list-style-type: none"> • Øyvinn A. Brøymer (Styreleder) • Bettina Banoun • Kari Krogstad • Espen Marcussen • Espen Lia Gregoriussen (ansatte representant) • Stine Wang Rønningen (ansatte representant) 	<ul style="list-style-type: none"> • Øyvinn A. Brøymer, Chairman (re-elected) • Bettina Banoun (re-elected) • Kari Krogstad (re-elected) • Espen Marcussen (re-elected) <p>The Board consists of the following shareholder and employee elected members:</p> <ul style="list-style-type: none"> • Øyvinn A. Brøymer (Chairman) • Bettina Banoun • Kari Krogstad • Espen Marcussen • Espen Lia Gregoriussen (employee representative) • Stine Wang Rønningen (employee representative)
<p>10. Fullmakt til å utstede aksjer</p>	<p>10. Authorization to issue shares</p>
<p>Følgende vedtak ble truffet:</p> <p>"Styret gis fullmakt til å øke aksjekapitalen med inntil NOK 8 868 918 gjennom én eller flere aksjekapitalutvidelser.</p> <p>Fullmakten skal kunne anvendes for følgende formål:</p> <p>(i) for å gi Selskapet finansiell fleksibilitet, herunder ved investeringer, oppkjøp og fusjoner.</p> <p>Pris og tegningsvilkår fastsettes av styret ved hver utstedelse under hensyn til Selskapets behov og aksjenes markedsverdi på det aktuelle tidspunkt. Aksjer vil kunne utstedes mot kontantvederlag eller vederlag i form av andre aktiva (tingsinnskudd).</p> <p>Eksisterende aksjonærs fortrinnsrett til å tegne aksjer vil kunne bli fraveket av styret i forbindelse med utøvelse av fullmakten.</p> <p>Denne fullmakten utløper på datoen for den ordinære generalforsamlingen i 2027, men skal i alle tilfelle utløpe senest 15 måneder fra datoen for denne generalforsamlingen.</p> <p>Styret gis samtidig fullmakt til å foreta nødvendige vedtektsendringer ved utøvelse av fullmakten."</p>	<p>The following resolution was passed:</p> <p>"The Board is granted authorization to increase the share capital with up to NOK 8 868 918, through one or several share capital increases.</p> <p>The authorization may be used for one or more of the following purposes:</p> <p>(i) to provide the Company with financial flexibility, including in connection with investments, mergers and acquisitions.</p> <p>Price and conditions for subscription will be determined by the Board on issuance, according to the Company's needs and the shares' market value at the time. Shares may be issued in exchange for cash settlement or contribution in kind.</p> <p>The existing shareholders pre-emptive rights to subscribe shares can be deviated from in connection with the effectuation of this authorization.</p> <p>The Board's authorization is valid until the Annual General Meeting in 2027, but shall in any event expire at the latest 15 months from the date of this annual general meeting.</p> <p>The Board is at the same time given authorization to make the necessary amendments to the articles of association on execution of the authorization."</p>
<p>11. Fullmakt til å erverve egne aksjer</p>	<p>11. Authorization to acquire treasury shares</p>
<p>Følgende vedtak ble fattet:</p> <p>"Styret gis fullmakt til på Selskapets vegne å erverve aksjer i Vistin Pharma ASA til ett eller flere av følgende formål:</p> <p>(i) for å øke aksjonærenes avkastning.</p> <p>Fullmakten gjelder for kjøp av inntil 10 % av pålydende av Selskapets aksjekapital, jf. allmennaksjeloven §§ 9-2 og 9-3. Aksjer kan erverves til minst NOK 1 per aksje og maksimalt NOK 100 per aksje. Disse begrensninger skal justeres tilsvarende i tilfelle av aksjespleis, aksjesplitt og</p>	<p>The following resolution was passed:</p> <p>"The Board is granted authorization to acquire shares in Vistin Pharma ASA on behalf of the Company for one or more of the following purposes:</p> <p>(i) to increase return on investment for the Company's shareholders.</p> <p>The authorization covers purchase(s) of up to 10% of the face value of the share capital of the Company, cf. the public limited liability companies act §§ 9-2 and 9-3. Shares may be acquired at minimum NOK 1 per share and maximum NOK 100 per share. These limitations shall be</p>

<p><i>lignende transaksjoner. Aksjene skal erverves ved ordinær omsetning over børs.</i></p> <p><i>Styrets fullmakt gjelder frem til den ordinære generalforsamlingen i 2027, men skal i alle tilfelle utløpe senest 15 måneder fra datoen for denne generalforsamlingen. Beslutningen skal meldes til og registreres av Foretaksregisteret innen aksjer erverves i henhold til fullmakten."</i></p>	<p><i>adjusted in the event of share consolidation, share splits, and similar transactions. The shares shall be acquired through ordinary purchase on the stock exchange. The Board's authorization is valid until the annual general meeting in 2027, but shall in any event expire at the latest 15 months from the date of this General Meeting. The decision shall be notified to and registered by the Norwegian Register of Business Enterprises prior to acquiring any shares pursuant to this authorization."</i></p>
<p>Da det ikke forelå flere saker til behandling, takket møteleder for oppmøtet, og møtet ble hevet.</p>	<p>As there were no further matters on the agenda, the Chairman thanked the present shareholders for their participation, and the meeting was adjourned.</p>
<p>Vedlagt følger en detaljert oversikt over utfallet av avstemningene, herunder blant annet antall stemmer for og mot de respektive beslutningene, jf. allmennaksjeloven § 5-16.</p>	<p>Attached is a detailed overview of the results and voting, including the number of votes for and against the respective resolutions, cf. the Norwegian public limited companies act section 5-16.</p>
<p>*****</p>	<p>*****</p>
<p>Signatur følger på neste side.</p>	<p>The signature follows on the next page.</p>
<p></p>	<p></p>
<p></p>	<p></p>
<p></p>	<p></p>
<p></p>	<p></p>

* These minutes are prepared in Norwegian, with an English office translation. In case of discrepancies between the two versions, the Norwegian version shall prevail.

Signature page for Vistin Pharma ASA Annual General Meeting 2026

Oslo, 20. mai, 2026 / Oslo, May 20th, 2026

Øyvin A. Brøymer

Sign.

Magnus W. Tolleshaug

Sign.

Total Represented

ISIN:	<u>NO0010734122 VISTIN PHARMA ASA</u>
General meeting date:	20/05/2026 13.00
Today:	20.05.2026

Number of persons with voting rights represented/attended : 4

	Number of shares	% sc
Total shares	44,344,592	
- own shares of the company	0	
Total shares with voting rights	44,344,592	
Represented by own shares	14,664,280	33.07 %
Represented by advance vote	2,300,553	5.19 %
Sum own shares	16,964,833	38.26 %
Represented by proxy	7,535,422	16.99 %
Represented by voting instruction	7,000	0.02 %
Sum proxy shares	7,542,422	17.01 %
Total represented with voting rights	24,507,255	55.27 %
Total represented by share capital	24,507,255	55.27 %

Registrar for the company:

NORDEA BANK ABP, FILIAL NORGE

Signature company:

VISTIN PHARMA ASA

Protocol for general meeting VISTIN PHARMA ASA

ISIN:	<u>NO0010734122 VISTIN PHARMA ASA</u>
General meeting date:	20/05/2026 13.00
Today:	20.05.2026

Shares class	For	Against	Poll in	Abstain	Poll not registered	Represented shares with voting rights
Agenda item 2 Election of the chairman of the meeting and a person to co-sign the minutes						
Ordinær	24,507,255	0	24,507,255	0	0	24,507,255
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %	
total sc in %	55.27 %	0.00 %	55.27 %	0.00 %	0.00 %	
Total	24,507,255	0	24,507,255	0	0	24,507,255
Agenda item 3 Approval of the notice of the meeting and the agenda						
Ordinær	24,507,255	0	24,507,255	0	0	24,507,255
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %	
total sc in %	55.27 %	0.00 %	55.27 %	0.00 %	0.00 %	
Total	24,507,255	0	24,507,255	0	0	24,507,255
Agenda item 4 Approval of the annual financial statements and the Directors report for 2025						
Ordinær	24,507,255	0	24,507,255	0	0	24,507,255
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %	
total sc in %	55.27 %	0.00 %	55.27 %	0.00 %	0.00 %	
Total	24,507,255	0	24,507,255	0	0	24,507,255
Agenda item 5 Approval of remuneration for the Board of Directors, the Election Committee and the Remuneration Committee						
Ordinær	24,507,255	0	24,507,255	0	0	24,507,255
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %	
total sc in %	55.27 %	0.00 %	55.27 %	0.00 %	0.00 %	
Total	24,507,255	0	24,507,255	0	0	24,507,255
Agenda item 6 Approval of auditors remuneration						

Shares class	For	Against	Poll in	Abstain	Poll not registered	Represented shares with voting rights
Ordinær	24,507,255	0	24,507,255	0	0	24,507,255
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %	
total sc in %	55.27 %	0.00 %	55.27 %	0.00 %	0.00 %	
Total	24,507,255	0	24,507,255	0	0	24,507,255
Agenda item 7.1 The Boards statement regarding determination of salary and other compensation to leading employees: The General Meeting supports the stateme						
Ordinær	24,500,255	7,000	24,507,255	0	0	24,507,255
votes cast in %	99.97 %	0.03 %		0.00 %		
representation of sc in %	99.97 %	0.03 %	100.00 %	0.00 %	0.00 %	
total sc in %	55.25 %	0.02 %	55.27 %	0.00 %	0.00 %	
Total	24,500,255	7,000	24,507,255	0	0	24,507,255
Agenda item 7.2 The Boards statement regarding determination of salary and other compensation to leading employees:The General Meeting adopts the statement						
Ordinær	24,500,255	7,000	24,507,255	0	0	24,507,255
votes cast in %	99.97 %	0.03 %		0.00 %		
representation of sc in %	99.97 %	0.03 %	100.00 %	0.00 %	0.00 %	
total sc in %	55.25 %	0.02 %	55.27 %	0.00 %	0.00 %	
Total	24,500,255	7,000	24,507,255	0	0	24,507,255
Agenda item 8 Approval of financial assistance to purchase shares in relation to the companys long-term incentive plan.						
Ordinær	24,500,255	7,000	24,507,255	0	0	24,507,255
votes cast in %	99.97 %	0.03 %		0.00 %		
representation of sc in %	99.97 %	0.03 %	100.00 %	0.00 %	0.00 %	
total sc in %	55.25 %	0.02 %	55.27 %	0.00 %	0.00 %	
Total	24,500,255	7,000	24,507,255	0	0	24,507,255
Agenda item 9 Election of members to the Board of Directors						
Ordinær	24,507,255	0	24,507,255	0	0	24,507,255
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %	
total sc in %	55.27 %	0.00 %	55.27 %	0.00 %	0.00 %	
Total	24,507,255	0	24,507,255	0	0	24,507,255
Agenda item 10 Authorisation to issue shares						

Shares class	For	Against	Poll in	Abstain	Poll not registered	Represented shares with voting rights
Ordinær	24,504,780	2,475	24,507,255	0	0	24,507,255
votes cast in %	99.99 %	0.01 %		0.00 %		
representation of sc in %	99.99 %	0.01 %	100.00 %	0.00 %	0.00 %	
total sc in %	55.26 %	0.01 %	55.27 %	0.00 %	0.00 %	
Total	24,504,780	2,475	24,507,255	0	0	24,507,255
Agenda item 11 Authorisation to acquire treasury shares						
Ordinær	24,507,255	0	24,507,255	0	0	24,507,255
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %	
total sc in %	55.27 %	0.00 %	55.27 %	0.00 %	0.00 %	
Total	24,507,255	0	24,507,255	0	0	24,507,255

Registrar for the company:

NORDEA BANK ABP, FILIAL NORGE

Signature company:

VISTIN PHARMA ASA

Share information

Name	Total number of shares	Nominal value	Share capital	Voting rights
Ordinær	44,344,592	1.00	44,344,592.00	Yes
Sum:				

§ 5-17 Generally majority requirement

requires majority of the given votes

§ 5-18 Amendment to resolution

Requires two-thirds majority of the given votes

like the issued share capital represented/attended on the general meeting